Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China

References

• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–160. doi:10.23750/abm.v91i1.9397
   PubMedGoogle Scholar
• Farooqi T, Malik JA, Mulla AH, et al. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies. J Infect Public Health. 2021;14(10):1299–1312. doi:10.1016/j.jiph.2021.08.014
   PubMed Web of Science ®Google Scholar
• Dhama K, Nainu F, Frediansyah A, et al. Global emerging omicron variant of SARS-CoV-2: impacts, challenges and strategies. J Infect Public Health. 2023;16(1):4–14. doi:10.1016/j.jiph.2022.11.024
   PubMed Web of Science ®Google Scholar
• Pan Y, Wang L, Feng Z, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. The Lancet. 2023. doi:10.1016/S0140-6736(23)00129-0
   PubMed Web of Science ®Google Scholar
• Goldberg EE, Lin Q, Romero-Severson EO, et al. Swift and extensive omicron outbreak in China after sudden exit from 'zero-COVID' policy. Nat Commun. 2023;14(1):3888. doi:10.1038/s41467-023-39638-4
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Bhattacharya M, Chopra H, et al. Recently emerged omicron subvariant BF.7 and its R346T mutation in the RBD region reveal increased transmissibility and higher resistance to neutralization antibodies: need to understand more under the current scenario of rising cases in China and fears of driving a new wave of the COVID-19 pandemic. Int J Surg. 2023;109(4):1037–1040. doi:10.1097/js9.0000000000000219
   PubMed Web of Science ®Google Scholar
• Lu G, Ling Y, Jiang M, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland. Front Med. 2023: 1–10. doi:10.1007/s11684-022-0981-7
   PubMed Web of Science ®Google Scholar
• Fu D, He G, Li H, et al. Effectiveness of COVID-19 vaccination against SARS-CoV-2 omicron variant infection and symptoms - China, December 2022-February 2023. China CDC Wkly. 2023;5(17):369–373. doi:10.46234/ccdcw2023.070
   PubMedGoogle Scholar
• Gengler I, Wang JC, Speth MM, et al. Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: a systematic review of the current evidence. Laryngoscope Investig Otolaryngol. 2020;5(3):354–359. doi:10.1002/lio2.384
   PubMed Web of Science ®Google Scholar
• Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med. 2022;28(5):1031–1041. doi:10.1038/s41591-022-01780-9
   PubMed Web of Science ®Google Scholar
• Scendoni R, Cingolani M. What do we know about pathological mechanism and pattern of lung injury related to SARS-CoV-2 omicron variant? Diagn Pathol. 2023;18(1):18. doi:10.1186/s13000-023-01306-y
   PubMed Web of Science ®Google Scholar
• Ku Z, Xie X, Hinton PR, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595(7869):718–723. doi:10.1038/s41586-021-03673-2
   PubMed Web of Science ®Google Scholar
• Respaud R, Vecellio L, Diot P, et al. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12(6):1027–1039. doi:10.1517/17425247.2015.999039
   PubMed Web of Science ®Google Scholar
• Matucci A, Vultaggio A, Danesi R. The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. Respir Res. 2018;19(1):154. doi:10.1186/s12931-018-0859-z
   PubMedGoogle Scholar
• Leyva-Grado VH, Tan GS, Leon PE, et al. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother. 2015;59(7):4162–4172. doi:10.1128/aac.00290-15
   PubMed Web of Science ®Google Scholar
• Weltzin R, Traina-Dorge V, Soike K, et al. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 1996;174(2):256–261. doi:10.1093/infdis/174.2.256
   PubMed Web of Science ®Google Scholar
• Prince GA, Hemming VG, Horswood RL, et al. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol. 1987;61(6):1851–1854. doi:10.1128/jvi.61.6.1851-1854.1987
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Emergency use authorizations for drugs and non-vaccine biological products. https://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products.
   Google Scholar
• Imsuwansri T, Jongthitinon T, Pojdoung N, et al. Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers. Sci Rep. 2023;13(1):15648), doi:10.1038/s41598-023-42539-7
   PubMed Web of Science ®Google Scholar
• Song R, Zeng G, Yu J, et al. Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study. Emerg Microbes Infect. 2023;12(1):2212806), doi:10.1080/22221751.2023.2212806
   PubMed Web of Science ®Google Scholar
• Totschnig D, Augustin M, Niculescu I, et al. SARS-CoV-2 pre-exposure prophylaxis with sotrovimab and tixagevimab/cilgavimab in immunocompromised patients-A single-center experience. Viruses. 2022;14(10). doi:10.3390/v14102278
   PubMed Web of Science ®Google Scholar
• Jo Y, Kim SB, Jung J. A model-based cost-effectiveness analysis of long-acting monoclonal antibody (tixagevimab and cilgavimab: evusheld) preventive treatment for high-risk populations against SARS-CoV-2 in Korea. J Korean Med Sci. 2023;38(32):e250. doi:10.3346/jkms.2023.38.e250
   PubMed Web of Science ®Google Scholar
• Qu Y, Zhang X, Wang M, et al. Antibody cocktail exhibits broad neutralization activity against SARS-CoV-2 and SARS-CoV-2 variants. Virol Sin. 2021;36(5):934–947. doi:10.1007/s12250-021-00409-4
   PubMed Web of Science ®Google Scholar
• Lu J, Yin Q, Pei R, et al. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants. Virol Sin. 2022;37(2):238–247. doi:10.1016/j.virs.2022.02.005
   PubMed Web of Science ®Google Scholar
• Li X, Pan Y, Yin Q, et al. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse omicron sublineages. Cell Discov. 2022;8(1):87. doi:10.1038/s41421-022-00449-4
   PubMed Web of Science ®Google Scholar
• Chinese Center for Disease Control and Prevention. SARS-CoV-2 infections in China,2023,https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202301/t20230125_263519.html, (accessed April 15, 2023).
   Google Scholar
• Zhang Z, Li H, Ma H, et al. Genomic recombination of SARS-CoV-2 subvariants BA.5.2.48 and BF.7.14 - China, 2023. China CDC Wkly. 2023;5(14):318–320. doi:10.46234/ccdcw2023.058
   PubMedGoogle Scholar
• Ku Z, Xie X, Hinton PR, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595(7869):718–723. doi:10.1038/s41586-021-03673-2
   PubMed Web of Science ®Google Scholar
• De Gasparo R, Pedotti M, Simonelli L, et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021;593(7859):424–428. doi:10.1038/s41586-021-03461-y
   PubMed Web of Science ®Google Scholar
• Yang M, Li J, Huang Z, et al. Structural basis of a human neutralizing antibody specific to the SARS-CoV-2 spike protein receptor-binding domain. Microbiol Spectr. 2021;9(2):e0135221. doi:10.1128/Spectrum.01352-21
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–588. doi:10.1002/psp4.12224
   PubMedGoogle Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody combination and outcomes in outpatients with COVID-19. N Engl J Med. 2021;385(23):e81. doi:10.1056/NEJMoa2108163
   PubMed Web of Science ®Google Scholar
• Isa F, Forleo-Neto E, Meyer J, et al. Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. Int J Infect Dis. 2022;122:585–592. doi:10.1016/j.ijid.2022.06.045
   PubMed Web of Science ®Google Scholar
• Lin Y, Yue S, Yang Y, et al. Nasal spray of neutralizing monoclonal antibody 35B5 confers potential prophylaxis against severe acute respiratory syndrome coronavirus 2 variants of concern: a small-scale clinical trial. Clin Infect Dis. 2023;76(3):e336–e341. doi:10.1093/cid/ciac448
   PubMedGoogle Scholar
• Balmforth D, Swales JA, Silpa L, et al. Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: a multi-centre, double blind, placebo-controlled, randomised trial. J Clin Virol. 2022;155:105248. doi:10.1016/j.jcv.2022.105248
   PubMed Web of Science ®Google Scholar
• Figueroa JM, Lombardo ME, Dogliotti A, et al. Efficacy of a nasal spray containing iota-carrageenan in the postexposure prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease. Int J Gen Med. 2021;14:6277–6286. doi:10.2147/ijgm.S328486
   PubMed Web of Science ®Google Scholar